Last reviewed · How we verify
NCT05242185
Long Term Sequelae of COVID-19: Follow-up Study in Dhaka, Bangladesh
trial testing Observational study in COVID-19 in 398 participants. Status unknown.
4 April 2022
Quick facts
| Lead sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 398 |
| Start date | 8 February 2021 |
| Primary completion | 4 April 2022 |
| Estimated completion | 4 April 2022 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- Observational study — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh — full company profile →
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 or coronavirus disease 2019 is an emerging infectious disease. The disease was first identified in China and then spread worldwide; hence, declared as a global pandemic on March 11, 2020 by World Health Organization (WHO). The pandemic is posing formidable challenges to healthcare systems and humanities worldwide resulting in morbidities and mortalities unthought of. Rapidly accumulating clinical evidence on COVID-19 paved the way for an extensive and prompt characterization of the acute phase of the disease. The clinical presentation is generally that of a respiratory infection with a symptom severity ranging from a mild common cold-like illness, to a severe viral pneumonia leading to acute respiratory distress syndrome that is potentially fatal. Characteristic symptoms include fever, cough, and dyspnoea, although some patients may be asymptomatic. Complications of severe disease include, but are not limited to, multi-organ failure, septic shock, and acute respiratory distress syndrome. The COVID-19 infection fatality rate is between 0.5 and 1 percent and the remaining affected patients will mostly recover but need convalescent care. However, discharge should not be considered as the final point of overcoming coronavirus and till date evidence on sequelae of the COVID-19 recovered patients is very limited. COVID-19 is a complex multisystem disease that affects pulmonary function, as well as renal, cardiovascular, and neuropsychiatric health, metabolic derangement; and nutritional status. The extent to which these alterations may persist remains obscure, till date evidence on long term sequelae of the COVID-19 recovered patients is very limited. Some of the aftereffects of it may have a profound impact on 'recovered' patients in the future. Long-term morbidities were observed in survivors of severe acute respiratory syndrome but it is unidentified whether experience from SARS is applicable to COVID-19. The SARS-CoV-2 infection is severe in older, immune deficient people and who have any pre-existing medical conditions. Hence, it is imperative to comprehend the possible long-term sequelae of the COVID-19 recovered patients, and if they will develop any other harmful illnesses. This study would help us to understand the in-depth prognosis and sequelae of the disease, as well as help to uncover to what extent would COVID-19 recovered patients require post-acute care to recuperate from any further infections or multi-organ damage.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05242185
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational study
Trials testing the same drug.
- NCT07255443 — Intestinal Colonization With Carbapenem Resistant Enterobacteriaceae Among ICU Patients at Assiut University Hospital · not yet recruiting
- NCT07343713 — Correlation Between the Degree of Middle Ear Pressure and the Eustachian Tube Dimensions : Radiological Study · not yet recruiting
- NCT07192991 — Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America · not yet recruiting
- NCT07219927 — Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: · recruiting
- NCT06244238 — A Study on the Relationship Between Job Satisfaction and Retention Intentions of Emergency Room Nurses · unknown
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other International Centre for Diarrhoeal Disease Research, Bangladesh trials
Trials by the same sponsor.
- NCT07537686 — Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunc · Phase 2 · not yet recruiting
- NCT07345208 — Safety and Immunogenicity of ID vs IM Rabies Vaccine · Phase 2, PHASE3 · not yet recruiting
- NCT07045493 — Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh · Phase 2 · enrolling by invitation
- NCT06757283 — ZyVac-TCV Bangladesh Study · Phase 3 · not yet recruiting
- NCT06815835 — Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05242185 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International Centre for Diarrhoeal Disease Research, Bangladesh
- Last refreshed: 11 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05242185.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing